Model-Informed Precision Dosing of Imipenem in an Obese Adolescent Patient with Augmented Renal Clearance and History of Schizophrenia

被引:0
作者
Chen, Yueliang [1 ]
Han, Yun [2 ,3 ]
Guo, Feng [1 ]
Yu, Zhenwei [1 ,2 ,3 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Intens Care Unit, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pharm, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Res Ctr Clin Pharm, Hangzhou, Zhejiang, Peoples R China
来源
INFECTION AND DRUG RESISTANCE | 2024年 / 17卷
关键词
case report; imipenem; therapeutic drug monitoring; population pharmacokinetic; PHARMACOKINETICS; OPTIMIZATION;
D O I
10.2147/IDR.S450294
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Imipenem is a broad-spectrum antibiotic that has been used in treating severe infections and exhibits a time-dependent PK/ PD profile. Its dose should be adjusted based on renal function. However, there is little experience with imipenem dosing in obese adolescent patients with augmented renal clearance (ARC) and history of schizophrenia. This case reported successful dosing of imipenem in an obese adolescent patient with ARC based on therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD). A 15-year-old male adolescent patient with history of schizophrenia was diagnosed with ventilator-associated pneumonia due to carbapenem-susceptible Klebsiella pneumoniae and received imipenem treatment (0.5 g every 8 hours with a 1-hour infusion). However, the exposure of imipenem was suboptimal due to ARC, and there is no available model for MIPD in this patient. Thus, we utilized prediction error to find a population pharmacokinetic model that fit this patient and ran Maximum a posteriori Bayesian estimation and Monte Carlo simulation based on screened models to predict changes in drug concentrations. The dose of imipenem was adjusted to 0.5 g every 6 hours with a 2-hour infusion, and subsequent TDM revealed that dosing adjustment was accurate and successful. Finally, the patient's status of infection improved. This study will be beneficial to imipenem dosing in similar cases in the future, thereby improving the safety and effectiveness of imipenem or other antibiotics.
引用
收藏
页码:761 / 767
页数:7
相关论文
共 34 条
  • [1] Avedissian Sean N, 2020, J Pediatr Pharmacol Ther, V25, P413, DOI 10.5863/1551-6776-25.5.413
  • [2] Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically III Pediatric Patients
    Avedissian, Sean N.
    Bradley, Erin
    Zhang, Diana
    Bradley, John S.
    Nazer, Lama H.
    Tran, Tri M.
    Nguyen, Austin
    Le, Jennifer
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2017, 18 (09) : E388 - E394
  • [3] Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients
    Bai, Jing
    Wen, Aiping
    Li, Zhe
    Li, Xingang
    Duan, Meili
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (05) : 434 - 439
  • [4] Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation
    Bakdach, Dana
    Elajez, Reem
    Bakdach, Abdul Rahman
    Awaisu, Ahmed
    De Pascale, Gennaro
    Hssain, Ali Ait
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [5] Prevalence and Risk Factors for Augmented Renal Clearance in a Population of Critically Ill Patients
    Baptista, Joao Pedro
    Martins, Paulo Jorge
    Marques, Margarida
    Pimentel, Jorge Manuel
    [J]. JOURNAL OF INTENSIVE CARE MEDICINE, 2020, 35 (10) : 1044 - 1052
  • [6] Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children
    Beranger, Agathe
    Oualha, Mehdi
    Urien, Saik
    Genuini, Mathieu
    Renolleau, Sylvain
    Aboura, Radia
    Hirt, Deborah
    Heilbronner, Claire
    Toubiana, Julie
    Treluyer, Jean-Marc
    Benaboud, Sihem
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (07) : 867 - 875
  • [7] Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study
    Bricheux, A.
    Lenggenhager, L.
    Hughes, S.
    Karmime, A.
    Lescuyer, P.
    Huttner, A.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (03) : 383.e1 - 383.e4
  • [8] IMIPENEM CILASTATIN - A REAPPRAISAL OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY
    BUCKLEY, MM
    BROGDEN, RN
    BARRADELL, LB
    GOA, KL
    [J]. DRUGS, 1992, 44 (03) : 408 - 444
  • [9] Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations
    Cheng, Yu
    Wang, Chen-yu
    Li, Zi-ran
    Pan, Yan
    Liu, Mao-bai
    Jiao, Zheng
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (01) : 53 - 68
  • [10] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10